PubMed=21573635; DOI=10.3892/ijo.2.5.831
Pfragner R., Wirnsberger G.H., Behmel A., Wolf G., Passath A., Ingolic E., Adamiker D., Schauenstein K.
New continuous cell-line from human medullary-thyroid carcinoma -- SINJ -- phenotypic analysis and in vivo carcinogenesis.
Int. J. Oncol. 2:831-836(1993)

PubMed=12089864
Pfragner R., Wirnsberger G.H., Ingolic E., Niederle B.
Medullary thyroid carcinomas in cell culture -- models for future therapies.
Wien. Klin. Wochenschr. 114:279-283(2002)

PubMed=15126569; DOI=10.1210/jc.2003-031314
Kaczirek K., Schindl M., Weinhausel A., Scheuba C., Passler C., Prager G., Raderer M., Hamilton G., Mittlbock M., Siegl V., Pfragner R., Niederle B.
Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines.
J. Clin. Endocrinol. Metab. 89:2397-2401(2004)

PubMed=17786610; DOI=10.1080/14653240701385836
Stadler G., Wieser M., Steindl F., Grillari J., Katinger H., Pfragner R., Voglauer R.
Development of standarDIzed cell culture conditions for tumor cells with potential clinical application.
Cytotherapy 9:488-498(2007)

PubMed=22038905; DOI=10.1002/ijc.26494
Flicker K., Ulz P., Hoger H., Zeitlhofer P., Haas O.A., Behmel A., Buchinger W., Scheuba C., Niederle B., Pfragner R., Speicher M.R.
High-resolution analysis of alterations in medullary thyroid carcinoma genomes.
Int. J. Cancer 131:E66-E73(2012)

CLPUB00412
Siddiqui Z.G.
Medullary thyroid cancer: the current state of tumour marker and treatment strategies.
Thesis MD (2015), Medical University of Graz, Austria